An observational study in Necrotizing Soft Tissue Infection, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by University of California, Irvine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Soft Tissue Infections with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Soft Tissue Infections · United States.
Among the 39 studies in Soft Tissue Infections with a site in United States, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 34th registered.
92 studies on the registry are indexed under Soft Tissue Infections; 14 are open to participants now.
Browse Soft Tissue Infections studies →5 of the 39 studies in Soft Tissue Infections with a site in United States are open now. Recruiting first, the newest first:
HealthPartners Institute · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18–65
University of Utah · Sites in United States
Ages up to 18
Seattle Children's Hospital · Sites in United States
Ages 1–16
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Soft Tissue Infections studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6 · Phase 4 7
First in 2004; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 50 is below the median of 270 across 28 observational studies indexed under Soft Tissue Infections.
Median enrollment 160 across the 31 interventional studies, 280 across the 7 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 39 have an industry lead sponsor. The 10 most frequent:
University of California, Irvine is the lead sponsor of 478 studies on the registry; 99 are open to participants now.
Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.
University of California, Irvine has 1 study filed under Soft Tissue Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Soft Tissue Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07120386HealthPartners InstituteIrrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections | 2026-12 |
| NCT06002607University of California, IrvineShorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections | 2026-12-01 |
| NCT05471908University of UtahFollow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Soft Tissue Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Necrotizing soft tissue infection (NSTI) is a devastating disease that results in a high rate of in-hospital complications and despite advances in critical care, wound care, and early intervention, NSTI continues to be associated with a mortality rate of nearly 30%. The antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. Although one of the tenets of management for NSTI is early broad-spectrum intravenous antibiotics (listed above), the duration of antibiotics needed is not well defined. Currently, there exists wide variation in the duration of antibiotics for NSTI ranging between 2-16 days. The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI.
The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. The proposed shortened duration is considered within standard of care as the IDSA suggests 48-72 hours of antibiotics after source control, however this was due mostly to expert opinion until a recent single-center study using historical controls demonstrated a 48-hour duration of antibiotics to be safe. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI. This pilot study may help limit use of antibiotics which are associated with both cost and significant adverse events including antimicrobial resistance and clostridium difficile infections. In addition, the data would support grant submission of a larger, multi-center study with sufficient power to demonstrate the safety profile and potential benefits of a shorter duration of antibiotics, which has been shown to be beneficial in previous large surgical infection studies.
Specific Aims:
Aim#1: Establish the safety of an abbreviated course (48 hours after source control) compared to a prolonged (7 days after source control) course of antibiotics in terms of in-hospital mortality.
Aim#2: Compare the incidence of hospital length of stay and in-hospital complications including unplanned return to the operating room, ventilator days, and antibiotic associated complications (e.g., clostridium difficile infection) in the two comparison groups: abbreviated (48-hours) and prolonged antibiotics (7-days) after source control.
Aim#3: Identify a critical threshold of biochemical procalcitonin or a % decrease in procalcitonin from the initial procalcitonin obtained upon admission that suggests resolution of systemic infection in patients with NSTI. This will be done by obtaining a serum procalcitonin upon admission and daily for up to 7 days from admission or once source control has been achieved.
Adult patients with a diagnosis of Necortizing Soft Tissue Infection who undergo consultation by the Emergency General Surgery service.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients assigned to a 48-hour course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient
Other: Antibiotic duration (short course)
Patients assigned to a 7 day course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient
Other: Antibiotic duration (extended course)
The patient will be enrolled in a 48-hour course of antibiotics.
The patient will be enrolled in a 7 day course of antibiotics.
Safety of the antibiotic course duration
In-hospital complications
Time frame: Through study completion, an average of 1 year
Mortality rate
In-hospital mortality
Time frame: Through study completion, an average of 1 year
Age
Age in years
Time frame: Baseline, pre-intervention/procedure/surgery
Sex
Sex (male/female)
Time frame: Baseline, pre-intervention/procedure/surgery
BMI (body mass index)
Body mass index (weight and height will be combined to report BMI in kg/m\^2)
Time frame: Baseline, pre-intervention/procedure/surgery
Blood Pressure
Blood Pressure (mmHg)
Time frame: Baseline, pre-intervention/procedure/surgery
Heart Rate
Heart rate (beats/minute)
Time frame: Baseline, pre-intervention/procedure/surgery
Respiratory rate
Respiratory rate (breaths/minute)
Time frame: Baseline, pre-intervention/procedure/surgery
Temperature
Temperature (Fahrenheit)
Time frame: Baseline, pre-intervention/procedure/surgery
Comorbidities
Comorbidities (e.g., diabetes, hypertension, cirrhosis, chronic kidney disease, etc.)
Time frame: Baseline, pre-intervention/procedure/surgery
Transfusion requirements
Number of Packed Red Blood Cells transfused measured in milliliters
Time frame: Baseline, pre-intervention/procedure/surgery
NSTI location
Anatomical location of soft tissue infection
Time frame: Baseline, pre-intervention/procedure/surgery
Operations
Number of surgical procedures
Time frame: Through study completion, an average of 1 year
Serum concentration of procalcitonin
Procalcitonin ng/mL
Time frame: Upon admission and daily blood sample for 7 days
Serum concentration of white blood cell
White blood cell count cells per microliter (cells/μL)
Time frame: Through study completion, an average of 1 year
Serum concentration of hemoglobin
Hemoglobin grams/deciliter
Time frame: Through study completion, an average of 1 year
Serum concentration of sodium
Sodium millimoles per liter (mmol/L)
Time frame: Through study completion, an average of 1 year
Serum concentration of C-reactive protein
C-reactive protein milligrams/liter
Time frame: Through study completion, an average of 1 year
Serum concentration of glucose
Glucose milligrams/deciliter
Time frame: Through study completion, an average of 1 year
Serum concentration of creatinine
Creatinine milligram/deciliter
Time frame: Through study completion, an average of 1 year
Total hospital length of stay
Total days of hospital stay
Time frame: Through study completion, an average of 1 year
Total intensive care unit (ICU)
Total days of ICU stay
Time frame: Through study completion, an average of 1 year
Total ventilator days
Total days of ventilation support for the patient
Time frame: Through study completion, an average of 1 year
Plan to share: No — The overall study results will be listed on Clinicaltrials.gov
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Irvine →